

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

application, to remove multiple dependency from the claims and to conform the claims to the American practice.

Respectfully submitted,
BIERMAN, MUSERLIAN AND LUCAS



Charles A. Muserlian, #19,683
Attorney for Applicant(s)
Tel. # (212) 661-8000

CAM:sd

Enclosures: Marked-up Version of Specification and Claims
Return Receipt Postcard


New derivatives of echinocandine, their preparation process
and their use as antifungals.

--This application is a 371 of PCT/FR00/01569 filed June 8, 2000.--

The present invention relates to new derivatives of
5 echinocandine, their preparation process and their use as
antifungals.

A subject of the invention is in all the possible isomer
forms as well as their mixtures, the compounds of formula
(I) :

10




20

25 in which

either R₁ and R₂ identical to or different from one another,
represent a hydrogen atom, a hydroxyl radical, a linear,
branched or cyclic alkyl radical containing up to 8 carbon
atoms optionally interrupted by an oxygen atom optionally

30 substituted by a halogen atom, an OH radical, an



35 radical, a and b identical to or different from one another,
representing a hydrogen atom or an alkyl radical containing
up to 8 carbon atoms, a and b can optionally form with the
nitrogen atom a heterocycle optionally containing one or more


*Acceptor selected from the
group consisting of*

MARKED-UP VERSION
OF
CLAIMS

Our Ref.: 146.1376

1) ~~in~~ all possible isomeric forms as well as their mixtures ~~of~~ *of* the compounds of formula (I).

5



10


15


20 *wherein*
~~in which~~

either R_1 and R_2 identical to or different from one another,
represent a hydrogen atom, a hydroxyl radical, a linear,
branched or cyclic alkyl radical containing up to 8 carbon
atoms optionally interrupted by an oxygen atom and optionally
25 substituted by a halogen atom, *or* selected from the group consisting of


30

are individually
identical to or different from one another,
representing a hydrogen atom or an alkyl radical containing up to 8 carbon atoms, *or* a and b can optionally form with the nitrogen atom a heterocycle optionally containing at least one or more
35 additional heteroatoms,
or R_1 forms with the endocyclic carbon atom






5 *is selected for the group consisting of*
 represents an -XRa radical, X representing an oxygen atom or
 an -NH or -N-alkyl radical containing up to 8 carbon atoms and
 Ra represents a hydrogen atom, a linear, branched or cyclic
 alkyl radical containing up to 8 carbon atoms optionally
 10 substituted by *at least one member of the group consisting of* ^{alkyl}
 one or more halogen atoms, by one or more -OH ,
 $\text{-CO}_2\text{H}$, $\text{-CO}_2\text{alk}$, *and* radicals , by an





radical, a' and b' representing a hydrogen atom, an alkyl radical containing up to 8 carbon atoms, a' and b' can form a heterocycle optionally containing one or more additional heteroatoms, and/or by a heterocycle containing one or more











25 *radical in which d, e, f and g represent a hydrogen atom or an alkyl radical containing up to 8 carbon atoms, f and g can moreover represent an acyl radical containing up to 8 carbon atoms, and e and f can also form a ring optionally containing one or more heteroatoms,*

30 *R₃ represents a hydrogen atom, a methyl and hydroxyl, radical R₄ represents a hydrogen atom or a hydroxyl, radical R represents a radical chosen from the following radicals:*

35





T represents a hydrogen atom, a methyl radical, a $-\text{CH}_2\text{CONH}_2$, $-\text{CH}_2\text{CN}$ radical, a $-(\text{CH}_2)_2\text{NH}_2$ or $-(\text{CH}_2)_2\text{Nalk}^+\text{X}^-$ radical, X being a halogen atom and alk an alkyl radical containing up to 8 carbon atoms,

5 Y represents a hydrogen atom, a hydroxyl, radical or a halogen atom or an OSO_3H radical or one of the salts of this radical, and a OSO_3Na radical. W represents a hydrogen atom or an OH radical.

W represents a hydrogen atom or an -OH radical.

Z represents a hydrogen atom or CH_3 methyl radical and a non-toxic, pharmaceuticals accessible acid, as well as the addition salts thereof with acids of the products of

10 ~~formula (1)~~:

2) ~~The~~ compounds of formula (I) defined in claim 1 in which T represents a hydrogen atom.

3) The compounds of formula (I) defined in claim 1 or 2 in which W represents a hydrogen atom.

15 4) The compounds of formula (I) defined in any one of
claims 1 to 3, in which Z represents a methyl radical.

5) The compounds of formula (I) defined in any one of claims 1 to 4 in which Y represents a hydrogen atom.


6) The compounds of formula (I) defined in any one of

20 claims 1 to 5 in which R_3 represents a methyl radical.


7) The compounds of formula defined in any one of claims 1 to 6, in which R_4 represents a hydroxyl radical.

8) The compounds of formula (I) defined in any one of claims 1 to 7 in which R represents a group consisting of


25




30



35




5

radicalor a

10


and

15 radical.

9) The compounds of formula I defined in any one of claims 1 to 8 in which R₁ represents a hydrogen radical.


10) The compounds of formula I defined in any one of claims 1 to 9 in which R₂ represents a

20

radical.


11) The compounds of formula I defined in any one of claims 1 to 9 in which R₂ represents a

30



35




radical and in particular the
20th A congener of claim 11 wherein R₂ is




radicals.

12. ~~12) The compounds of formula I defined in any one of claims 1 to 9 in which R₂ represents the group consisting of~~

5



10


15 radical.

13. ~~13) The compounds of formula I defined in claim 1 the names of which follow:~~ ^{selected from}

- 1-[4-[(2-aminoethyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- trans-1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- 1-[4-[(2(S)-aminopropyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- 1-[4-[(2-aminoethyl)amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-1,3,4-thiadiazol-2-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- trans 1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-1,3,4-thiadiazol-2-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate ^{and}
- trans 1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[3-[4-

(pentyloxy)-phenyl]-1,2,4-oxadiazol-5-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate.

14 14) A process for the preparation of the compounds of formula (I) defined in any one of claims 1 to 13, characterized in that a compound of formula (II)



in which R, R₃, R₄, T, Y, W and Z are defined as in claim 1, meaning, is subjected to the action of an amine or of an amine derivative capable of introducing

25

~~the~~ $\begin{array}{c} R_1 \\ | \\ -N- \\ | \\ R_2 \end{array}$ radical in which R₁ and R₂ are defined as in claim 1


30 retain their previous meaning and optionally then with a reducing agent, and/or of a functionalization agent of the amine, and/or of an acid in order to form the salt of the product obtained,

35 and/or of a separation agent of the different isomers obtained, and in this way the compound of formula (I) as defined in claim 1 is obtained.


24

~~15) As new chemical products, the compounds of formula (II) whenever R, R₁, R₂, R₃, R₄, T, Y, μ and z are defined as in claim 14.~~

~~16) A process according to claim 14 characterized in that a compound, formula (III) of the~~




20 R_3, R_4, T, W, Y and Z are defined as in claim 14
in which the different substituents retain their previous
meaning is subjected with
replacing $-NH_2$ by $-NHR$, R retaining its previous meaning in
order to obtain the compound of formula (IV)



25
reacting the said compound with
which is subjected to the action of trimethylsilyl iodide in
order to obtain the corresponding compound of formula ~~II~~

5



10

15

17) As new chemical products the compounds of formula III and IV defined in claim 16.

18) As antifungal compounds, the compounds of formula (I) defined in any one of claims 1 to 13, as well as their addition salts with acids.

19) The pharmaceutical compositions containing at least one compound of formula (I) defined in any one of claims 1 to 13

20 25 as a medicament, as well as their addition salts with pharmaceutically acceptable acids.